Big Data and data science are increasingly disrupting established marketing and commercial practices in pharma organisations, affecting drug development, clinical trial design, health service delivery and diagnostics.
Information comes from new data sources – structured and unstructured, requested and unrequested – while powerful analytic tools can be put to work to make sense of what would be an otherwise unmanageable mass of data.
Analysing and integrating data from a variety of real-world sources allows pharma companies to better understand stakeholders they interact with and to become more customer and patient-centric. Primary research also has a central role, filling in any gaps and adding the ‘human stories’ behind the data.
Our paper presents a three-stage analytics pathway and Ipsos’ expert guidance on how best to manage data for business insights in pharma.
The authors state that:
The unconventional combination of data science and qualitative research will be key for marketing insight professionals of the future, with qualitative research likely to become the best friend of a data scientist, and vice versa.
Global vaccines research
As the race to develop a COVID-19 vaccine continues at speed, the world faces many more questions than answers – not only about when we might have a vaccine, but who will get it first, how will they get it and are they willing to have it? And how far will it take us on the journey back to ‘normal’…?